Clinical Trial Technology Editorial

  1. Contracting For AI In Clinical Trials: Cybersecurity, Monitoring, And Risk Allocation (Part 3) 5/15/2026

    Leibowitz Law shares the third installment of its three-part series on contracting for AI in clinical trial operations. Part 3 picks up with cybersecurity, monitoring and validation, and risk allocation.

  2. Contracting For AI In Clinical Trials: Data Rights And Regulatory Compliance (Part 2) 5/15/2026

    Leibowitz Law's three-part series examines how AI is being used in clinical trial operations and the contractual and operational risks that follow. Part 2 demonstrates why organizations must understand where it is used, how it interacts with data, and where the risks lie.

  3. Where AI Appears In Clinical Trials — And Why Contracts Need To Catch Up (Part 1) 5/15/2026

    Leibowitz Law's three-part series examines how AI is being used in clinical trial operations and the contractual and operational risks that follow. Part 1 outlines where AI appears in ClinOps and supporting technologies, and the questions companies and organizations should ask when AI touches data.

  4. When AI Agents Start Researching Trials On Behalf Of Patients, What Happens? 5/13/2026

    Right now, patients are using AI agents to find clinical trials. But soon enough, these AI tools will be doing it on their own and feeding patients the results. Recruitment expert Ross Jackson discusses this shift and what it will mean for sponsors.

  5. Safe And Scalable AI Deployment For Clinical Trials 5/11/2026

    When life sciences organizations lack a structured, evidence-based methodology for scaling AI tools safely and effectively, they put clinical development at risk. Partha Anbil and Partha Khot team up to share a practical approach to its implementation.

  6. Small Biotech Survival: Navigating Risk And Capital Scarcity With AI 5/8/2026

    Maxine Opperman discusses the challenge and the necessity of small biotech's using AI, citing its pros, cons, and strategies for use.

  7. Human-In-The-Loop In AI Validation And Control: From Principle To Practice 4/28/2026

    Explores how human-in-the-loop oversight can move from principle to practice. with a risk-based framework for determining when HITL is required, how the human role should be defined, and what organizational factors influence its effectiveness.

  8. Reimagining Data Governance For The AI Era 4/24/2026

    Understand the persistent governance challenges that undermine AI initiatives and walk away with a robust blueprint for building a resilient, scalable, and ethically sound framework.

  9. Navigating Elsa's AI Transition: Practical Guidance To Safeguard Confidential Information (Part 3) 4/22/2026

    With FDA's Claude-to-Gemini transition underway within Elsa, Kimberly Chew, Esq., and Michael Yang, Esq., offer advice for proactive risk management to safeguard trade secrets and regulatory outcomes in part three of this series on Elsa's AI transition.

  10. Is It Time To Replace RECIST — Or Just Add AI? 4/16/2026

    Immunocore Chief Regulatory and Quality Officer Mark Moyer explains why new tools, including AI-based approaches, may better capture cancer treatment response than existing measures, such as ir-RECIST.